Exposure–response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations
Wenyuan Xiong(Merck Serono S.A. (Switzerland)), Rainer Strotmann(Leipzig University), Karin Berghoff(Merck KGaA, Darmstadt (Germany)), Sofia Friberg Hietala, Karthik Venkatakrishnan(Ono Pharmaceutical (United States)), Joakim Nyberg(Uppsala University), Orestis Papasouliotis(Merck Serono S.A. (Switzerland)), Kosalaram Goteti(Ono Pharmaceutical (United States)), Jennifer Dong(Ono Pharmaceutical (United States)), Pascal Girard(Merck Serono S.A. (Switzerland)), Andreas Johne(Merck KGaA, Darmstadt (Germany))
Cited by 12
Related Papers
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
|New England Journal of Medicine|2020|879
Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
|Journal of Clinical Oncology|2019|154
A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours
|British Journal of Cancer|2020|127
Mutually Opposite Signal Modulation by Hypothalamic Heterodimerization of Ghrelin and Melanocortin-3 Receptors
|Journal of Biological Chemistry|2011|109